Sarepta Therapeutics (SRPT) Institutional Ownership
13F filers reported holding 34.0% of Sarepta Therapeutics (SRPT) shares as of Sep 30, 2026, across 196 filers.
- Held by 13F filers
- 34.0%
- Sep 30, 2026
- 13F filers
- 196
- quarter ended Sep 30, 2026
- 13F value
- $664.3M
- 36.4M shares
- Quarter's fund flow
- Mild distribution
- 21 new · 24 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | Disposed · Tax withholding | 13,272 | $22.22 | ↗ |
| Sep 4, 2026 | Estepan Ian Michael | Chief Operating Officer | Disposed · Tax withholding | 24,799 | $22.22 | ↗ |
| Sep 4, 2026 | Rothfuss Cristin | EVP, General Counsel | Disposed · Tax withholding | 22,025 | $22.22 | ↗ |
| Sep 4, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | Disposed · Tax withholding | 21,423 | $22.22 | ↗ |
| Jul 28, 2026 | SEVERINO MICHAEL | Chief Executive Officer | Acquired · Grant / award | 756,104 | — | ↗ |
| Jul 28, 2026 | SEVERINO MICHAEL | Chief Executive Officer | Acquired · Grant / award | 2,224,342Stock Options (right to buy) | — | ↗ |
| Jun 4, 2026 | Boor Kathryn Jean | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Jun 4, 2026 | Mayo Stephen | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Jun 4, 2026 | Wigzell Hans Lennart Rudolf | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Jun 4, 2026 | BEHRENS M KATHLEEN | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Jun 4, 2026 | Connelly Deirdre P | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Jun 4, 2026 | Nicaise Claude | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Jun 4, 2026 | Chambers Michael Andrew | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Jun 4, 2026 | Barry Richard | director | Acquired · Grant / award | 16,875 | — | ↗ |
| Mar 12, 2026 | Mayo Stephen | director | Disposed · Open-market sale | 7,239 | $17.02 | ↗ |
| Mar 11, 2026 | Estepan Ian Michael | Chief Operating Officer | Disposed · Tax withholding | 1,097 | $17.03 | ↗ |
| Mar 11, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | Disposed · Tax withholding | 256 | $17.03 | ↗ |
| Mar 11, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | Disposed · Tax withholding | 948 | $17.03 | ↗ |
| Mar 11, 2026 | Rothfuss Cristin | EVP, General Counsel | Disposed · Tax withholding | 974 | $17.03 | ↗ |
| Mar 9, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | Disposed · Tax withholding | 162 | $16.95 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Sarepta Therapeutics do institutions hold?
13F filers reported holding 34.0% of Sarepta Therapeutics' shares as of Sep 30, 2026, across 196 filers.
How many 13F filers hold Sarepta Therapeutics?
Sarepta Therapeutics was held by 196 13F filers as of Sep 30, 2026.
Not investment advice.

